Rare diseases: Opportunistic or Philanthropic?
This article was originally published in Scrip
Executive Summary
With special incentives associated with orphan drug status and the technological advances underpinned by better understanding of the underlying genetics, it is not surprising that rare diseases have become an increasingly attractive target for the pharma and biotech companies. However, while most companies' entry into the orphan drug field has been primarily motivated by the potential for technology breakthroughs and the business opportunity, the societal impact is also a potential major driver.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.